While Covid-related sales may come down going ahead, analysts expect the company's domestic sales to outperform the market, led by the chronics portfolio, which accounts for 55 per cent of sales.

Rising commodity costs, coupled with other marketing-related expenses, could weigh on profitability in the coming quarters.

Jio is planning to win over 350 million 2G feature phone users by launching a smartphone at a fraction of the current cost.

While margins contracted by 30 basis points on y-o-y basis, they fell a sharper 120 basis points on a sequential basis to 16.8 per cent. Profitability was impacted adversely due to subdued demand, tepid realisations in commodity sectors, and negative operating leverage.

The weakness in the stock was because of inspections by the American drug regulator at its Halol plant in Gujarat which resulted in eight observations, as well as a downward revision of speciality drug payoffs.

With little clarity on the demand outlook, investors should wait out the next couple of quarters rather than rush in to catch a falling knife, says Ram Prasad Sahu.

Price cuts post the November GST rate rationalisation helped improve volume growth for HUL, what pegged back sales for ITC is adverse social media rumours against Aashirvaad atta, its single-largest FMCG brand.

From MRF to Shree Cement: 23 companies which delivered 30% CAGR in 15 years.

Street may be ignoring TCS headwinds as the stock's peak valuation doesn't seem justified by BFSI weakness, likely higher US tax rates and stronger rupee, reports Ram Prasad Sahu.

Falling revenues, increased capex, and first full year of spectrum debt may make things worse

The load factor for IndiGo in Q1 stood at 83.3 per cent.

Almost a third of the company's capex was stuck in this project

Godrej Properties, is on the horizon as it unlocks value in its high-value Bandra-Kurla Complex (BKC) project.

Given its network and fleet, it has garnered the highest share of passenger growth.

Brokerages have cut the company's FY16 earnings estimates between 16% and 29% with target prices too coming down to the Rs 700-800 band

FIIs are looking at the long-term story and initiatives of Indian pharma companies to transform themselves into global entities.

Telcos have indicated that rates will have to be raised, as higher volumes alone will not suffice to meet the higher costs.

The challenge of merging Ranbaxy into the company has not been factored in.

Given the better growth in JLR sales and improving domestic sales, nearly 90 per cent of the analysts covering the stock have a 'Buy' rating.

Maruti has improved its sales in the recent past.